BMS Collaborates with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer
Shots:
- MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development- regulatory- and sales milestone along with royalties on future sales
- MTEM will be responsible for research activities to discover next-generation ETBs for multiple targets- of which BMS selected the first target. BMS to get an option to obtain an exclusive WW license to develop and commercialize ETBs directed to each selected target
- Following the exercise of the option- BMS would be solely responsible for developing and commercializing the licensed ETBs. The companies will utilize MTEM’s next-generation ETB platform for specific oncology targets
Ref: GlobeNewswire | Image: Molecular Templates
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com